| Market Cap | 10.93B | P/E | - | EPS this Y | -39.00% | Ern Qtrly Grth | - |
| Income | -254.85M | Forward P/E | -54.17 | EPS next Y | 18.70% | 50D Avg Chg | 5.00% |
| Sales | 112.76M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 30.00% |
| Dividend | N/A | Price/Book | 15.22 | EPS next 5Y | - | 52W High Chg | -6.00% |
| Recommedations | 2.50 | Quick Ratio | 10.92 | Shares Outstanding | 61.16M | 52W Low Chg | 60.00% |
| Insider Own | 11.70% | ROA | -18.40% | Shares Float | 49.92M | Beta | 0.13 |
| Inst Own | 88.28% | ROE | -31.59% | Shares Shorted/Prior | 1.87M/1.73M | Price | 178.75 |
| Gross Margin | -104.32% | Profit Margin | -226.01% | Avg. Volume | 1,246,106 | Target Price | 178.88 |
| Oper. Margin | -226.57% | Earnings Date | Feb 23 | Volume | 7,884,284 | Change | 0.00% |
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adult patients with beta-thalassemia and transfusion-dependent anemia. The company is also developing Sotatercept, an activin receptor type IIA fusion protein, for the treatment of patients with pulmonary arterial hypertension; ACE-1334, a pulmonary therapeutic candidate that is in Phase I clinical trials; and luspatercept-aamt for non-transfusion-dependent beta-thalassemia patients and lower-risk myelodysplastic syndrome patients. It has a license agreements with the Salk Institute for Biological Studies for the cloning of type II activin receptors; and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. As of November 19, 2021, Acceleron Pharma Inc. operates as a subsidiary of Merck Sharp & Dohme Corp.
| Jefferies | Hold | Oct 7, 21 |
| Raymond James | Market Perform | Oct 4, 21 |
| Morgan Stanley | Equal-Weight | Oct 1, 21 |
| Barclays | Equal-Weight | Oct 1, 21 |
| Cowen & Co. | Market Perform | Oct 1, 21 |
| HC Wainwright & Co. | Neutral | Sep 30, 21 |
| Piper Sandler | Neutral | Sep 30, 21 |
| SVB Leerink | Market Perform | Sep 30, 21 |
| RBC Capital | Sector Perform | Sep 27, 21 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Zakrzewski Joseph S | Director Director | Apr 05 | Option | 24.11 | 10,000 | 241,100 | 44,499 | 04/05/21 |
| Veness Adam M | SVP, General Counsel.. SVP, General Counsel and Sec. | Jan 06 | Sell | 123.23 | 2,056 | 253,361 | 16,163 | 01/06/21 |
| MCLAUGHLIN KEVIN F | SVP, CFO and Treasur.. SVP, CFO and Treasurer | Jan 06 | Sell | 123.44 | 4,779 | 589,920 | 5,813 | 01/06/21 |
| Dable Habib J | CEO and President CEO and President | Jan 06 | Sell | 121.77 | 4,258 | 518,497 | 81,788 | 01/06/21 |
| MCLAUGHLIN KEVIN F | SVP, CFO and Treasur.. SVP, CFO and Treasurer | Dec 15 | Option | 34.99 | 42,528 | 1,488,055 | 53,744 | 12/15/20 |
| MCLAUGHLIN KEVIN F | SVP, CFO and Treasur.. SVP, CFO and Treasurer | Dec 15 | Sell | 130.14 | 42,528 | 5,534,594 | 11,216 | 12/15/20 |
| MCLAUGHLIN KEVIN F | SVP, CFO and Treasur.. SVP, CFO and Treasurer | Dec 11 | Option | 35.68 | 7,472 | 266,601 | 14,316 | 12/11/20 |
| MCLAUGHLIN KEVIN F | SVP, CFO and Treasur.. SVP, CFO and Treasurer | Dec 11 | Sell | 125.05 | 7,472 | 934,374 | 11,216 | 12/11/20 |
| Kearney Terrence C | Director Director | Oct 13 | Option | 28.84 | 37,500 | 1,081,500 | 42,627 | 10/13/20 |
| Kearney Terrence C | Director Director | Oct 13 | Sell | 119.32 | 37,500 | 4,474,500 | 5,127 | 10/13/20 |